Tβ-4 Antibody (4H7): sc-293251
- Tβ-4 Antibody (4H7) is a mouse monoclonal IgG2b κ Tβ-4 antibody provided at 100 µg/ml
- raised against amino acids 1-44 of Tβ-4 of human origin
- recommended for detection of Tβ-4 of mouse, rat and human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Tβ-4 Antibody (4H7). This work is in progress.
Tβ-4 Antibody (4H7) is a mouse monoclonal IgG2b kappa light chain antibody that detects T beta-4 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-T beta-4 antibody (4H7) is available as a non-conjugated format. Thymosin β-4 (Tβ-4) is a crucial member of the thymosin β family, which consists of highly conserved polar peptides that play a significant role in cellular dynamics by binding to monomeric actin and inhibiting polymerization. This function regulates G-actin availability, influencing cellular processes such as migration, adhesion, and cytoskeletal organization. Tβ-4 is predominantly found in cell cytoplasm, participating in essential biological functions, including wound healing, angiogenesis, and inflammatory response modulation. Notably, Tβ-4 shows increased expression in numerous human carcinomas, highlighting potential as a biomarker for cancer progression and therapeutic target. Given these multifaceted roles in cellular events and implications in health and disease, Tβ-4 continues to emerge as a protein of significant biological and pharmaceutical relevance.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Tβ-4 Antibody (4H7) References:
- beta-Thymosins, small acidic peptides with multiple functions. | Huff, T., et al. 2001. Int J Biochem Cell Biol. 33: 205-20. PMID: 11311852
- Chemotherapeutic drugs change actin skeleton organization and the expression of beta-thymosins in human breast cancer cells. | Otto, AM., et al. 2002. J Cancer Res Clin Oncol. 128: 247-56. PMID: 12029440
- Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. | Wang, WS., et al. 2003. Oncogene. 22: 3297-306. PMID: 12761500
- The actin binding site on thymosin beta4 promotes angiogenesis. | Philp, D., et al. 2003. FASEB J. 17: 2103-5. PMID: 14500546
- Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. | Wang, WS., et al. 2004. Oncogene. 23: 6666-71. PMID: 15235586
- A comparative analysis of RNA targeting strategies in the thymosin beta 4 gene. | Gibbons, DL., et al. 2004. J Mol Biol. 342: 1069-76. PMID: 15351635
- Nuclear localisation of the G-actin sequestering peptide thymosin beta4. | Huff, T., et al. 2004. J Cell Sci. 117: 5333-41. PMID: 15466884
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. | Bock-Marquette, I., et al. 2004. Nature. 432: 466-72. PMID: 15565145
- Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin beta-4. | Cierniewski, CS., et al. 2007. Ann N Y Acad Sci. 1112: 123-39. PMID: 17495245
- Thymosin beta 4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. | Tang, MC., et al. 2011. Cancer Lett. 308: 162-71. PMID: 21621326
- Thymosin β4 is a novel potential prognostic marker in gastrointestinal stromal tumors. | Can, B., et al. 2012. APMIS. 120: 689-98. PMID: 22882257
- MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer. | Gemoll, T., et al. 2015. Oncotarget. 6: 43869-80. PMID: 26556858
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tβ-4 Antibody (4H7) | sc-293251 | 100 µg/ml | $322.00 |